Advocates Led by AARP Support Medicare’s Drug Price Negotiation Program

This week, the Center for Medicare Advocacy, alongside a coalition led by AARP, filed an amicus brief in support of Medicare’s new drug price negotiation program, as established by the Inflation Reduction Act (IRA). The program, challenged in court by AstraZeneca Pharmaceuticals, aims to lower prescription drug costs for older adults and people with disabilities. It addresses the burden of high drug prices on Medicare beneficiaries, who often struggle with costly coinsurance payments, and seeks to protect Medicare’s financial integrity while potentially saving taxpayers billions.